Clinical Trial Update: Specifying the Anti-inflammatory Effects of Ziltivekimab [Phase 3]

View source ↗

Summary

Phase 3 trial update describing anti-inflammatory effects of Ziltivekimab in atherosclerosis-related inflammation conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Inflammation

Drugs mentioned

• Ziltivekimab

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Atherosclerosis, Inflammation | Phase 3 | Status: ACTIVE_NOT_RECRUITING